This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| GAK | |
|---|---|
| Name | GAK |
| Alt | Cyclin G-associated kinase |
| Uniprot | Q9UEW3 |
| Organism | Homo sapiens |
GAK is a human protein kinase involved in intracellular trafficking, mitosis, and protein folding. It has been studied in cell biology, oncology, neurology, and virology contexts and is conserved across metazoans and yeast. GAK interacts with clathrin, heat shock proteins, cyclins, and multiple signalling and trafficking proteins, linking membrane traffic to cell cycle regulation and protein homeostasis.
The name derives from "Cyclin G-associated kinase", reflecting early biochemical identification alongside Cyclin G, Cyclin-dependent kinase 5 complexes and associations with the Heat shock protein 70 family. Historical nomenclature intersects with studies on clathrin-mediated endocytosis and was influenced by work in laboratories studying endocytosis such as those of Sandra Schmid, Robinson (biochemist) and Francis Brodsky. Alternate aliases encountered in databases and literature include auxilin-2 in contrast to Auxilin (auxilin-1), reflecting paralogy with neuronal proteins characterized by groups studying Drosophila melanogaster and Caenorhabditis elegans.
GAK encodes a serine/threonine kinase containing a kinase domain, a J-domain homologous to DnaJ cochaperones, and clathrin-binding motifs. It functions in uncoating clathrin-coated vesicles through interactions with Clathrin heavy chain and recruiting Hsc70/Hsp70 chaperones, integrating the chaperone cycle with vesicle trafficking characterized in studies by teams like Pishvaee and Ungewickell. GAK also localizes to centrosomes and the mitotic spindle, implicating it in processes involving Aurora kinase A, Cyclin B1, and components of the mitotic checkpoint such as Mad2 and BubR1. At the molecular level GAK phosphorylates substrates implicated in vesicle dynamics and cell cycle progression; biochemical analyses reference kinome mapping efforts by groups including Manning (kinase) and Cohen (biochemist). Structural studies relate domains to those characterized for J domain cochaperones and the architecture of clathrin-binding motifs determined in comparative work with Auxilin proteins.
Altered GAK expression or function has been linked to neurodegenerative disorders, cancer, and infectious disease susceptibility. Genetic and proteomic studies associate GAK loci with Parkinsonism risk in genome-wide association studies by consortia including IPDGC and cohorts such as UK Biobank and PGC. In oncology, GAK expression correlates with proliferation markers in studies of hepatocellular carcinoma, non-small cell lung carcinoma, and prostate cancer, with mechanistic links to EGFR signalling, endocytic trafficking of receptor tyrosine kinases, and mitotic control. Viral replication studies implicate GAK in the life cycles of RNA viruses studied by groups working on Dengue virus, Hepatitis C virus, and SARS-CoV-2, where GAK-dependent trafficking influences viral entry and egress.
Functional insights derive from model organisms and experimental reagents: knockout and knockdown of the orthologue in Mus musculus, conditional alleles characterized by projects like the International Mouse Phenotyping Consortium, and RNAi/CRISPR screens in Drosophila melanogaster and Caenorhabditis elegans. Yeast studies using the auxilin homolog marked key discoveries via genetic screens pioneered by laboratories such as Molecular Genetics groups at major centers. Research tools include antibodies developed by vendors and academic labs, small-molecule kinase inhibitors profiled in chemical genetics screens by the Chemical Genomics Centre and kinase inhibitor compendia from Sanger Institute programmes, and fluorescence-tagged constructs used in live-cell imaging by microscopy labs like those of Eric Betzig and Jennifer Lippincott‑Schwartz.
GAK is a candidate therapeutic target for cancer and antiviral strategies. Small-molecule inhibitors with activity against GAK kinase domain emerged from high-throughput screens by pharmaceutical companies including GlaxoSmithKline and collaborative academic groups; repurposed kinase inhibitors with off-target GAK activity were evaluated in trials or preclinical models involving NCI-sponsored programmes. Neuroprotective strategies consider modulation of GAK-related pathways in Parkinson's disease cohorts evaluated by neurology consortia such as Michael J. Fox Foundation-funded studies. Biomarker research examines GAK expression in tumour panels from initiatives like The Cancer Genome Atlas and biomarker consortia.
Genome-wide association studies implicate single-nucleotide polymorphisms near or within the GAK locus in Parkinson disease susceptibility across international cohorts including IPDGC, 23andMe datasets, and population biobanks such as UK Biobank and deCODE genetics. Population genetics analyses reference allele frequencies catalogued in resources like gnomAD, 1000 Genomes Project, and ExAC, and linkage studies examine GAK region haplotypes in familial Parkinsonism pedigrees collected by academic neurologic centers. Functional genomics efforts apply eQTL mapping from projects like GTEx to link regulatory variants to GAK expression in tissues including substantia nigra and liver.
GAK was first isolated in biochemical purifications associating with Cyclin G and clathrin uncoating complexes in studies from the late 1990s and early 2000s by research teams at institutions such as Harvard Medical School and Max Planck Institutes. Key milestones include identification of the J-domain and clathrin-binding motifs, demonstration of essential roles in clathrin-mediated trafficking in yeast and metazoans, genetic association with Parkinson disease in large-scale GWAS consortia, and development of small-molecule inhibitors in chemical genomics campaigns. Subsequent decades saw expansion into cancer biology, viral host factor screens, and structural-functional dissection using cryo-electron microscopy techniques advanced by laboratories like RCSB PDB contributors.
Category:Human proteins